Tesofensine 500mcg x30 Capsules

Tesofensine is a triple reuptake inhibitor of serotonin, dopamine, and norepinephrine — originally developed as an anti-Parkinson treatment before its mechanism of action was discovered to produce significant weight loss in clinical trials. By blocking the reuptake transporters for all three monoamine neurotransmitters simultaneously, tesofensine elevates synaptic levels of serotonin (appetite suppression via hypothalamic 5-HT signaling), dopamine (reward pathway modulation and reduced compulsive eating), and norepinephrine (sympathomimetic energy expenditure increase and appetite suppression) — producing converging neurochemical effects that are among the most powerful appetite-suppressing mechanisms pharmacologically achievable.

The discovery of tesofensine's weight loss potential was serendipitous. In Phase 2 Parkinson's trials, patients treated with tesofensine demonstrated unexpected and substantial weight loss as an adverse effect — levels of weight reduction that significantly exceeded what had been seen with any previous single anti-obesity drug. Subsequent Phase 2 obesity trials (TIPO-1, published in The Lancet 2008) confirmed and quantified this effect: tesofensine at 0.5mg/day produced 10.6% weight loss over 24 weeks, far exceeding the weight loss of all comparator anti-obesity drugs available at the time (orlistat, sibutramine, rimonabant) in equivalent trials. This result established tesofensine as one of the most potent non-GLP-1 weight loss pharmacological agents ever evaluated.

The mechanisms that produce such powerful weight loss are multi-convergent. Serotonin reuptake inhibition activates hypothalamic 5-HT2C receptors (the same target as lorcaserin, now withdrawn) to reduce hunger signaling. Norepinephrine reuptake inhibition produces sympathomimetic CNS effects that increase metabolic rate, reduce appetite through β-adrenergic hypothalamic pathways, and increase energy expenditure through thermogenic mechanisms. Dopamine reuptake inhibition modulates the mesolimbic reward circuit — reducing food reward salience and compulsive eating behavior driven by hedonic rather than homeostatic hunger. Together, these three mechanisms address both homeostatic (hypothalamic hunger regulation) and hedonic (reward-driven eating) components of food intake simultaneously.

The cardiovascular profile of triple monoamine reuptake inhibitors requires careful attention. The norepinephrine and dopamine components produce sympathomimetic cardiovascular effects: increased heart rate, blood pressure elevation, and potential arrhythmic risk at high doses — the same class concerns that led to sibutramine's market withdrawal despite its efficacy. Tesofensine at the 0.5mg Phase 2 dose showed modest cardiovascular effects that were deemed manageable, but this remains the primary safety consideration for any development at this mechanism.

Tesofensine is in Phase 3 development for obesity (NeuroSearch AS / Saniona). The 500mcg capsule format reflects the established Phase 2 efficacy dose. Available as a research compound.